Literature DB >> 33587783

Platelet FcγRIIA in immunity and thrombosis: Adaptive immunothrombosis.

Pravin Patel1, James V Michael1, Ulhas P Naik1, Steven E McKenzie1.   

Abstract

Sepsis and autoimmune diseases remain major causes of morbidity and mortality. The last decade has seen a new appreciation of platelets in host defense, in both immunity and thrombosis. Platelets are first responders in the blood to microbes or non-microbial antigens. The role of platelets in physiologic immunity is counterbalanced by their role in pathology, for example, microvascular thrombosis. Platelets encounter microbes and antigens via both innate and adaptive immune processes; platelets also help to shape the subsequent adaptive response. FcγRIIA is a receptor for immune complexes opsonized by IgG or pentraxins, and expressed in humans by platelets, granulocytes, monocytes and macrophages. With consideration of the roles of IgG and Fc receptors, the host response to microbes and autoantigens can be called adaptive immunothrombosis. Here we review newer developments involving platelet FcγRIIA in humans and humanized mice in immunity and thrombosis, with special attention to heparin-induced thrombocytopenia, systemic lupus erythematosus, and bacterial sepsis. Human genetic diversity in platelet receptors and the utility of humanized mouse models are highlighted.
© 2021 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  FcγRIIA; heparin-induced thrombocytopenia; immunothrombosis; platelets; sepsis

Year:  2021        PMID: 33587783     DOI: 10.1111/jth.15265

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  5 in total

Review 1.  Platelets in Viral Infections - Brave Soldiers or Trojan Horses.

Authors:  Waltraud C Schrottmaier; Anna Schmuckenschlager; Anita Pirabe; Alice Assinger
Journal:  Front Immunol       Date:  2022-03-28       Impact factor: 7.561

2.  Spontaneous Platelet Aggregation in Blood Is Mediated by FcγRIIA Stimulation of Bruton's Tyrosine Kinase.

Authors:  Rundan Duan; Luise Goldmann; Ya Li; Christian Weber; Wolfgang Siess; Philipp von Hundelshausen
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

3.  Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia.

Authors:  Andreas Greinacher; Kathleen Selleng; Raghavendra Palankar; Jan Wesche; Stefan Handtke; Martina Wolff; Konstanze Aurich; Michael Lalk; Karen Methling; Uwe Völker; Christian Hentschker; Stephan Michalik; Leif Steil; Alexander Reder; Linda Schönborn; Martin Beer; Kati Franzke; Andreas Büttner; Boris Fehse; Evi X Stavrou; Chandini Rangaswamy; Reiner K Mailer; Hanna Englert; Maike Frye; Thomas Thiele; Stefan Kochanek; Lea Krutzke; Florian Siegerist; Nicole Endlich; Theodore E Warkentin; Thomas Renné
Journal:  Blood       Date:  2021-12-02       Impact factor: 25.476

4.  Antiplatelet therapy for patients with COVID-19: Systematic review and meta-analysis of observational studies and randomized controlled trials.

Authors:  Xiaolong Zong; Xiao Wang; Yaru Liu; Zhenyu Li; Weiding Wang; Dianjun Wei; Zhuqing Chen
Journal:  Front Med (Lausanne)       Date:  2022-09-07

Review 5.  Targeting SARS-CoV-2-Platelet Interactions in COVID-19 and Vaccine-Related Thrombosis.

Authors:  Dermot Cox
Journal:  Front Pharmacol       Date:  2021-07-05       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.